Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

Exclusive: China's Huawei in talks to sell premium smartphone brands P and Mate - sources

01/25/2021 | 07:29am EDT
FILE PHOTO: FILE PHOTO: Huawei logo is pictured on the headquarters building in Reading

(Reuters) - China's Huawei Technologies Co Ltd is in early-stage talks to sell its premium smartphone brands P and Mate, two people with direct knowledge of the matter said, a move that could see the company eventually exit from the high-end smartphone-making business.

The talks between the world's largest telecommunications equipment maker and a consortium led by Shanghai government-backed investment firms have been going on for months, the people said, declining to be identified as the discussions were confidential.

Huawei started to internally explore the possibility of selling the brands as early as last September, according to one of the sources. The two sources were not privy to the valuation placed on the brands by Huawei.

Shipments of Mate and P Series phones were worth $39.7 billion between Q3 2019 and Q3 2020, according to consultancy IDC.

However, Huawei has yet to make a final decision on the sale and the talks might not conclude successfully, according to the two sources, as the company is still trying to manufacture at home its in-house designed high-end Kirin chips which power its smartphones.

"Huawei has learned there are unsubstantiated rumours circulating regarding the possible sale of our flagship smartphone brands," a Huawei spokesman said. "There is no merit to these rumours whatsoever. Huawei has no such plan."

The Shanghai government said it was not aware of the situation and declined to comment further.

The potential sale of Huawei's premium smartphone lines suggests the company has little hope that the new Biden administration will have a change of heart towards the supply chain restrictions placed on Huawei since May 2019, the two people said.

The Shanghai government-backed investment firms may form a consortium with Huawei's dealers to take over the P and Mate brands, according to the second person, a similar model to the Honor deal. Huawei is also likely to keep its existing P& Mate management team for the new entity, if the deal goes through, the two people said.


Huawei, the world's biggest telecoms equipment vendor and No.2 smartphone maker, last November announced the sale of its budget phone brand Honor to a consortium of 30 dealers led by a company backed by the Shenzhen government.

The second source said the all-cash sale fetched more than 100 billion yuan ($15.5 billion). Honor declined to comment.

The Honor sale was aimed at keeping the budget brand alive, as sanctions slapped on Huawei by the United States had hampered the unit's supply chain and cut off the company's access to key hardware like chips and software such as Alphabet Inc's Google Mobile Services.

Huawei may have a similar objective in pursuing the sale of the mobile brands. The two sources said that Huawei's latest plans for the two high-end brands were motivated by insufficient chip supplies.

Washington says that Huawei is a national security threat, which Huawei has repeatedly denied.

On Friday, Honor indicated that the goal of the spin-off had been reached by announcing it had formed partnerships with chip makers such as Intel and Qualcomm and launched a new phone.

Last year, the company's Consumer Business Group Chief Executive Richard Yu said U.S. restrictions meant Huawei would soon stop making Kirin chips. Analysts expect its stockpile of the chips to run out this year.

Huawei's HiSilicon division relies on software from U.S. companies such as Cadence Design Systems Inc or Synopsys Inc to design its chips and it outsources the production to Taiwan Semiconductor Manufacturing Co (TSMC), which uses equipment from U.S. companies.

The P and Mate phone series are among the top players in the higher-end smartphone market in China and compete with Apple's iPhone, Xiaomi Corp's Mi and Mix series and OPPO's Find series.

The two brands contributed nearly 40% to Huawei's total sales over the third quarter of 2020, according to market research firm Counterpoint.

Analysts have already noted recent insufficient supplies of the flagship P40 and Mate40 series due to a severe components shortage.

"We expect a continuous decline in sales of P and Mate series smartphones through Q1 2021," said Flora Tang, an analyst at Counterpoint.

(Reporting by Julie Zhu, Yingzhi Yang and David Kirton, Additional reporting by Brenda Goh; Editing by Sumeet Chatterjee & Shri Navaratnam)

By Julie Zhu, Yingzhi Yang and David Kirton

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
APPLE INC. 1.17% 145.16 Delayed Quote.8.09%
CADENCE DESIGN SYSTEMS, INC. 0.95% 162.42 Delayed Quote.17.91%
KIRIN HOLDINGS COMPANY, LIMITED -0.85% 2031.5 End-of-day quote.-16.54%
MSCI TAIWAN (STRD) -2.28% 691.324 Real-time Quote.17.73%
SYNOPSYS INC. 0.87% 320.5 Delayed Quote.23.94%
TAIWAN SEMICONDUCTOR CO., LTD. -3.36% 63.2 End-of-day quote.1.61%
UNITED STATES DOLLAR (B) / CHINESE YUAN IN HONG KONG (USD/CNH) -0.36% 6.4578 Delayed Quote.-0.21%
XIAOMI CORPORATION 1.32% 23.1 End-of-day quote.-30.42%
Latest news "Economy & Forex"
01:22pRestaurant-software maker Toast valued at nearly $33 billion as shares surge in debut
01:22pU.S. existing home sales fall in August, house price inflation moderating
01:21pBank of England says to boost competition in banking, adapt to Brexit
01:19pBluebell capital says believes gsk's emma walmsley would have been a very credible candidate for the position of ceo at consumer healthcare
01:16pApple bars Epic's "Fortnite" until all court appeals end
01:14pBluebell writes to gsk in relation to investment and/or economic interest in gsk common equity shares by bluebell active equity master fund icav
01:12pBluebell capital says views gsk vaccine franchise as generally undervalued by market - letter
01:06pBLUEBELL CAPITAL : Asks gsk to take a proactive approach to consider available alternative transactions to demerger of consumer healthcare
01:05pExplainer-Why record high British natgas prices caused a crisis over CO2 supplies
01:04pBLUEBELL CAPITAL : Asks gsk to launch immediately afterwards thorough, robust process to identify best(internal or external) candidate to lead new gsk
Latest news "Economy & Forex"